# US Genotyping Market

> US Genotyping Market Research Report: Size, Share, Trend Analysis By Technology (Sequencing, Capillary Electrophoresis, PCR, Others), By Product (Reagents and Kits, Instruments, Services), By Applications (Diagnostics, Drug Discovery and Development, Academic Research, Research and Development Centers) and By End Userss (Hospitals, Diagnostic Centers, Academic Institutes, Research and Development Centers) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.89%
- **2024:** $ 677.59 Million
- **2025:** $ 737.83 Million
- **2035:** $ 1,728.56 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Qiagen (DE), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN)

**Report ID:** MRFR/LS/17124-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-genotyping-market-18652

---

## Market Summary

## **US Genotyping Market Overview**

As per MRFR analysis, the US Genotyping Market Size was estimated at 622.22 (USD Million) in 2023. The US Genotyping Market Industry is expected to grow from 677.6(USD Million) in 2024 to 6,330 (USD Million) by 2035. The US Genotyping Market CAGR (growth rate) is expected to be around 22.524% during the forecast period (2025 - 2035).

### **Key US Genotyping Market Trends Highlighted**

The US Genotyping Market is experiencing significant growth driven by the increasing adoption of personalized medicine and advances in genomic technologies. Key market drivers include a growing emphasis on precision healthcare, which utilizes genetic information to tailor medical treatments to individual patients.
The rise in genetic testing for inherited disorders, alongside extensive research initiatives and funding from organizations like the National Institutes of Health (NIH), further propels the market. There is also a noticeable shift towards direct-to-consumer genetic testing, allowing individuals to access their genetic information without a healthcare provider, creating a demand for user-friendly genotyping solutions.

Opportunities to be explored include the enhancement of genomic databases and biobanks for more comprehensive research and increased collaboration between biotechnology companies and healthcare institutions, leading to innovative product developments. Additionally, regulatory frameworks are evolving to accommodate new genetic testing technologies, making it a fertile ground for startups and established companies. Recent trends indicate that there is growing consumer interest in genetic health risks, ancestry testing, and wellness products, significantly impacting the US Genotyping Market.

Moreover, the integration of artificial intelligence in genomics analysis is providing tools for more accurate interpretations of genetic data, thus driving engagement in the field of genotyping.The convergence of these elements shapes a dynamic landscape, paving the way for advancements and ensuring that the US remains a leader in the global genotyping sector.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Genotyping Market Drivers**

#### **Increasing Prevalence of Genetic Disorders**

The rise in genetic disorders across the United States is significantly driving the US Genotyping Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 10 Americans, which translates to around 32 million people, are affected by a genetic disorder. This growing demographic is fueling demand for genotyping technologies to diagnose and understand genetic conditions better. Notably, institutions like the National Institutes of Health (NIH) have ramped up funding for genetic research, aiming to tackle complex genetic diseases, thereby propelling the growth of the market.

Increased investment in genetic testing can lead to greater application of genotyping technologies, which is essential for personalized medicine and targeted therapies. The trend reflects the larger movement toward genomic medicine in the US, with an estimated annual expenditure of over 2.5 billion USD on genetic testing-related services in recent years, indicating a robust market growth trajectory.

#### **Advancements in Genotyping Technologies**

Technological innovations in genotyping processes are playing a pivotal role in the expansion of the US Genotyping Market Industry. The introduction of next-generation sequencing (NGS) and single nucleotide polymorphism (SNP) arrays has revolutionized the efficiency and accuracy of genetic testing. According to the National Human Genome Research Institute, technological advancements have reduced sequencing costs by over 99% in the past decade, making genetic testing more accessible to the general public.

This abrupt decrease in costs, coupled with the rising demand for personalized medicine, is motivating both healthcare providers and patients to invest in genotyping services. Furthermore, leading biotechnological companies, such as Illumina and Thermo Fisher Scientific, are continuously enhancing their product offerings, thereby expanding the market spaces within the US.

#### **Growing Awareness and Acceptance of Personalized Medicine**

The burgeoning understanding and acceptance of personalized medicine among healthcare professionals and patients is significantly bolstering the US Genotyping Market Industry. More than 70% of healthcare providers are now advocating for the integration of genetic testing into routine healthcare practices, as reported by the American Medical Association. This shift in perception is essential for the market's future, particularly as patients are increasingly interested in tailored healthcare solutions.

Organizations such as the Precision Medicine Initiative, launched by the US government, have emphasized the importance of personalizing treatment plans based on individual genetic profiles, thereby integrating genotyping into mainstream medicine. The overall acceptance underscores the potential of the US genotyping market to transform patient care, with estimates suggesting this segment could experience growth rates up to 25% in the next decade.

### **US Genotyping Market Segment Insights**

#### **Genotyping Market Technology Insights**

The US Genotyping Market, particularly within the Technology segment, has been witnessing remarkable growth driven by advancements in genomic technologies and increased applications across various fields such as healthcare and agriculture. Sequencing technology has emerged as a pivotal component in the market, significantly impacting genetic research, clinical diagnostics, and personalized medicine. Its ability to quickly and accurately analyze DNA sequences allows for enhanced understanding of genetic disorders and the development of targeted therapies, making it a preferred choice among researchers and healthcare professionals.

Additionally, Capillary Electrophoresis continues to play a vital role in genotyping due to its high resolution and efficiency in separating DNA fragments, particularly in applications such as forensic analysis and paternity testing. This method is favored for its precision and reliability in producing clear and interpretable results.

The Polymerase Chain Reaction (PCR) technology stands out for its essential function in amplifying DNA, thereby making it easier to study genetic material in various biological samples. PCR's adaptability and speed in producing specific DNA sequences empower it to dominate many diagnostic and research applications. Moreover, other technologies within the market, including microarray and SNP genotyping methods, provide researchers with diverse tools to explore genetic variations and their implications. The demand for and adoption of these technologies are fueled by ongoing developments in research and development, which facilitate new discoveries in genomics.

Market trends indicate a growing preference for innovative genotyping solutions, which can enhance efficiency while reducing costs. Increasing investments in genomics by governmental bodies and private sectors in the US further bolster the US Genotyping Market, fostering an environment ripe for technological advancements. However, challenges such as regulatory hurdles and the need for skilled professionals pose potential setbacks in the market's growth. Overall, the Technology segment remains a significant driver of the US Genotyping Market, with continuous advancements and applications promising further opportunities for growth and development in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Genotyping Market Product Insights**

The US Genotyping Market showcases a diverse Product segment that plays a crucial role in advancing genetic research and diagnostics. This segment encompasses various categories including Reagents and Kits, Instruments, and Services, each contributing significantly to the market's growth. Reagents and Kits often serve as the backbone of genetic analysis, providing essential components for accurate genotyping processes and facilitating a wide range of applications, from genetic testing to drug development. Instruments, on the other hand, are central to enhancing the efficiency and precision of genotyping assays, as they allow for high-throughput analysis, which is vital in clinical and research settings.

Services, which include testing and consulting, deliver tailored solutions and expertise essential for interpreting complex genetic data, thus supporting researchers and healthcare providers. The trend towards personalized medicine and increasing demand for genetic testing in the US are strong growth drivers for this segment, offering numerous opportunities for innovation and expansion. This landscape illustrates the significance of the Product segment in shaping the future of the US Genotyping Market.

#### **Genotyping Market Application Insights**

The Application segment of the US Genotyping Market showcases a diverse range of functions crucial for advancing healthcare and research. Diagnostics plays a significant role by facilitating early disease detection through genetic screening, thus enhancing patient outcomes and tailoring treatment plans. In the realm of Drug Discovery and Development, genotyping accelerates the identification of genetic variations that influence drug response, significantly improving therapeutic efficacy and safety. Academic Research benefits immensely as it underpins studies probing genetic disorders, population genomics, and personalized medicine, fostering innovation and scientific breakthroughs.

Research and Development Centers are pivotal in this landscape, concentrating resources and expertise to translate genomic information into actionable insights, addressing critical health challenges. This segment is characterized by robust growth drivers, including technological advancements, increasing awareness of precision medicine, and supportive regulatory frameworks, making the US a frontrunner in global genotyping initiatives. The evolving landscape is further influenced by challenges such as data management and privacy concerns, while opportunities lie in expanding access to genomic technologies and enhancing collaboration between academic institutions and industry stakeholders.

#### **Genotyping Market End Users Insights**

The End Users segment of the US Genotyping Market plays a crucial role in the overall dynamics of the industry, focusing on key players such as Hospitals, Diagnostic Centers, Academic Institutes, and Research and Development Centers. Hospitals hold significant importance, as they utilize genotyping for personalized medicine, which elevates patient care and treatment efficacy. Diagnostic Centers are vital for disease detection and management, leveraging genotyping to improve diagnostic accuracy and patient outcomes. Academic Institutes drive innovation by conducting crucial research that fuels advancements in genetic studies and applications.

Research and Development Centers focus on developing new technologies and methodologies to enhance genotyping processes, addressing challenges such as cost and efficiency. 

The increasing demand for precision medicine and the overarching trend towards genomics in healthcare and research are key growth drivers within this segment. With continuous technological advancements and rising government support for genomic research, opportunities within these end-user categories are expanding, fostering further investment and expansion in the US Genotyping Market. The various segments not only support the market growth trajectory but also exemplify the diverse applications and impacts of genotyping across the healthcare and scientific research landscape in the United States.

### **US Genotyping Market Key Players and Competitive Insights**

The US Genotyping Market is characterized by a dynamic landscape where innovation and technological advancements play a crucial role in shaping competitive strategies. As the demand for personalized medicine and genetic testing continues to grow, companies within this market are focusing on developing more efficient and precise genotyping technologies. The competitive insights reveal that key players are emphasizing partnerships, collaborations, and strategic acquisitions to enhance their market presence and expand their product portfolios. 

Companies are also investing significantly in research and development to introduce novel solutions that cater to varying consumer needs, thereby creating a robust competitive environment. With several established players and new entrants striving for market share, understanding the competitive dynamics becomes essential for stakeholders looking to thrive in this sector.

Illumina stands out as a leading figure within the US Genotyping Market, recognized for its cutting-edge sequencing technologies and genotyping solutions. The company's robust market presence is attributed to its significant investment in research and development, which has allowed it to maintain a technological edge over competitors. Illumina’s strength lies in its ability to offer a comprehensive suite of products that cater to the diverse needs of researchers and clinicians. The company has successfully engaged with various sectors, including academic institutions, clinical laboratories, and biotechnology firms, ensuring widespread adoption of its technologies.

With a strong commitment to innovation and customer satisfaction, Illumina has solidified its role as a critical player in delivering high-quality, efficient genotyping solutions in the United States.

Helix operates within the US Genotyping Market with a focus on providing direct-to-consumer genetic testing services. The company is known for its unique approach that combines advanced genotyping technology with a consumer-friendly interface, allowing individuals to access and understand their genetic information seamlessly. Helix's key products include a range of genetic tests that address various aspects of health and ancestry. The company has established itself in the market through strategic partnerships and collaborations with healthcare providers and research institutions. Helix's strengths lie in its innovative business model and user-centric offerings, which provide personalized insights based on genetic data.

Additionally, Helix has strengthened its market position through various mergers and acquisitions, enhancing its technological capabilities and expanding its service offerings within the US region, continuously driving growth and development in the genotyping space.

#### **Key Companies in the US Genotyping Market Include**

- [Illumina](https://sapac.illumina.com/techniques/popular-applications/genotyping.html)
- Helix
- BioRad Laboratories
- Fulgent Genetics
- Biosystems
- New England Biolabs
- PerkinElmer
- Genetic Technologies
- Thermo Fisher Scientific
- Agilent Technologies
- Genomatix
- HTG Molecular Diagnostics
- Molecular Templates
- Qiagen
- BGI

### **US Genotyping Market Industry Developments**

In recent months, the US Genotyping Market has witnessed significant developments, particularly with companies like Illumina, Thermo Fisher Scientific, and Qiagen. Notably, Illumina has launched new products enhancing genome sequencing accuracy, further solidifying its market position. In March 2023, Thermo Fisher Scientific announced its acquisition of a smaller biotech firm to expand its genotyping capabilities, augmenting its product offerings in the precision medicine space. This move is part of a broader trend where companies like Fulgent Genetics and Helix are increasing their Research and Development investments, which have been reported to enhance product pipelines and overall market competition. 

Growth in the market valuation of these companies reflects the rising demand for genotyping in areas such as personalized medicine and clinical diagnostics. Furthermore, the National Institutes of Health reported that federal funding for genomic research has substantially increased over the past two years, facilitating advancements in genotyping technology. 
Also, key partnerships between companies like Agilent Technologies and New England Biolabs have emerged to foster innovation in high-throughput genotyping solutions, indicating a collaborative approach to market challenges. All these developments highlight a vibrant and rapidly evolving landscape in the US Genotyping Market.

### **US Genotyping Market Segmentation Insights**

#### **Genotyping Market Technology Outlook**

- Sequencing
- Capillary Electrophoresis
- PCR
- Others

#### **Genotyping Market Product Outlook**

- Reagents and Kits
- Instruments
- Services

#### **Genotyping Market Application Outlook**

- Diagnostics
- Drug Discovery and Development
- Academic Research
- Research and Development Centers

#### **Genotyping Market End Users Outlook**

- Hospitals
- Diagnostic Centers
- Academic Institutes
- Research and Development Centers

## Market Drivers

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders in the US is a pivotal driver for the genotyping market. As awareness of genetic conditions grows, healthcare providers are more inclined to utilize genotyping technologies for diagnosis and treatment. Reports indicate that approximately 1 in 33 infants is born with a genetic disorder, which underscores the necessity for advanced genetic testing. This trend is likely to propel the demand for genotyping services, as early detection can lead to better health outcomes. Furthermore, the genotyping market is expected to witness a compound annual growth rate (CAGR) of around 10% over the next five years, driven by the need for effective genetic screening and personalized treatment options.

### Growing Demand for Companion Diagnostics

The rise of companion diagnostics is reshaping the landscape of the genotyping market. These tests, which are designed to determine the suitability of specific therapies for individual patients, are increasingly being integrated into treatment protocols. The market for companion diagnostics is projected to reach $6 billion by 2026, reflecting a growing recognition of the importance of personalized medicine. As pharmaceutical companies collaborate with diagnostic firms, the demand for genotyping services is expected to escalate. This trend not only enhances patient outcomes but also drives the need for more sophisticated genotyping technologies, thereby propelling market growth.

### Increased Investment in Genomic Research

Investment in genomic research is a significant catalyst for the growth of the genotyping market. Federal funding and private sector investments have surged, with the National Institutes of Health (NIH) allocating substantial resources to genomics research. This financial support fosters innovation in genotyping technologies, enhancing their accuracy and efficiency. The US government has committed over $1 billion annually to genomic research initiatives, which is likely to stimulate advancements in genotyping methodologies. As research progresses, the applications of genotyping are expanding, leading to a broader acceptance in clinical settings and a projected market growth of 12% annually.

### Expansion of Direct-to-Consumer Genetic Testing

The expansion of direct-to-consumer (DTC) genetic testing is a notable driver for the genotyping market. Consumers are increasingly seeking insights into their genetic makeup for health, ancestry, and lifestyle purposes. The DTC genetic testing market is anticipated to exceed $1 billion by 2025, indicating a robust interest among the public. This trend encourages companies to innovate and offer more comprehensive genotyping services. As consumers become more informed about their genetic risks, the demand for professional genetic counseling and testing services is likely to rise, further stimulating the genotyping market.

### Advancements in Bioinformatics and Data Analysis

Advancements in bioinformatics and data analysis are crucial for the evolution of the genotyping market. The ability to analyze vast amounts of genetic data efficiently is transforming how genotyping results are interpreted and utilized. With the integration of artificial intelligence and machine learning, the accuracy and speed of genetic data analysis are improving significantly. This technological evolution is expected to enhance the overall efficiency of genotyping processes, making them more accessible and cost-effective. As a result, the market is projected to grow at a rate of 11% annually, driven by the increasing reliance on data-driven insights in genetic research and clinical applications.

## Future Outlook

The [Genotyping Market](https://www.marketresearchfuture.com/reports/genotyping-market-6635) is projected to grow at an 8.89% CAGR from 2025 to 2035, driven by advancements in technology, increasing demand for personalized medicine, and rising research funding.

**New opportunities:**

- Development of high-throughput genotyping platforms for large-scale studies. Expansion of direct-to-consumer genotyping services targeting health-conscious consumers. Partnerships with biotech firms to enhance genotyping applications in drug development.

By 2035, the genotyping market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Technology: Sequencing (Largest) vs. Capillary Electrophoresis (Fastest-Growing)

The US genotyping market is predominantly driven by the Sequencing segment, which commands the largest share due to its extensive applications in research and clinical diagnostics. Capillary Electrophoresis follows closely, catering to specific niche applications but is rapidly gaining traction and expanding its market share, fueled by innovative technological advancements and an increasing focus on genetic analysis.

Growth in the US genotyping market is being markedly influenced by technological advancements and the rising prevalence of genetic disorders, propelling the demand for effective genotyping methods. Sequencing continues to innovate, with next-gen technologies streamlining processes and efficiency. Meanwhile, Capillary Electrophoresis is recognized as the fastest-growing segment, driven by its adaptability and precision in analyzing genetic materials, appealing to both researchers and healthcare providers.

Technology: Sequencing (Dominant) vs. Capillary Electrophoresis (Emerging)

Sequencing is the dominant technology within the US genotyping market, characterized by its high throughput capabilities and versatility in various applications such as whole-genome sequencing and targeted sequencing. It stands out for its ability to generate vast quantities of data, fundamentally transforming genetic research and personalized medicine. On the other hand, Capillary Electrophoresis is an emerging technology, valued for its accuracy and efficiency in separating nucleic acids and proteins. Its growing adoption in forensic analysis and clinical diagnostics highlights its potential, as it becomes indispensable in the evolving landscape of genetic analysis, benefiting from advancements that improve speed and reliability.

### By Product: Reagents and Kits (Largest) vs. Instruments (Fastest-Growing)

In the US genotyping market, the distribution of market share among the product segments reveals that reagents and kits dominate significantly. This segment is favored for its critical role in genetic analysis, providing essential materials for accurate and efficient genotyping processes. Instruments, while currently holding a smaller share, are quickly gaining traction due to technological advancements and increased investments in automation and precision within laboratories.

Growth trends in this market are becoming increasingly favorable for instruments owing to innovations such as real-time PCR and next-generation sequencing technologies. These advancements not only enhance the speed and accuracy of genetic testing but also broaden the application range of these instruments in clinical diagnostics and research environments. Furthermore, the rise in personalized medicine initiatives is driving demand for diverse reagents and kits, solidifying their market position while fostering competition across both segments.

Reagents and Kits (Dominant) vs. Instruments (Emerging)

Reagents and kits serve as the backbone of the US genotyping market, characterized by their extensive utilization across research and clinical settings. They are integral for various applications, including disease diagnostics and genetic research. The focus on quality and reproducibility sets a high benchmark for manufacturers in this segment. Conversely, instruments are emerging rapidly as essential tools in the market, supported by continuous technological innovations. As laboratories embrace automation and require enhanced throughput, instruments that offer improved performance and reliability are poised for significant growth. Both segments play pivotal roles in shaping the future landscape of the industry, with reagents and kits maintaining dominance while instruments surge ahead, driven by new capabilities.

### By Application: Drug Discovery and Development (Largest) vs. Academic Research (Fastest-Growing)

In the US genotyping market, the distribution of market share among the application segments indicates that Drug Discovery and Development holds a significant portion of the market, reinforcing its importance in biopharmaceutical advancements. This segment is pivotal due to the increasing importance of personalized medicine and the growing demand for innovative therapeutic solutions, enabling researchers to develop targeted treatments based on genetic information.

On the other hand, Academic Research is emerging as the fastest-growing segment, driven by the surging investment in academic institutions and research facilities. This growth is supported by the expansive initiatives for genetic research and an increasing number of collaborations between academia and industry, which are collectively unlocking new avenues for discovery and technological innovation in genomics.

Drug Discovery: Dominant vs. Academic Research: Emerging

The Drug Discovery and Development segment remains dominant in the US genotyping market, characterized by its extensive utilization of genomic data to inform drug development processes and enhance therapeutic efficacy. This segment benefits from robust funding, knowledgeable professionals, and advanced technologies, which streamlines the transition from research to market-ready products. Conversely, the Academic Research segment is emerging rapidly, marked by a surge in innovative studies and collaborative projects that expand the understanding of genetics. This segment thrives on grant funding and partnerships, enabling it to explore novel methodologies and applications that may significantly impact both medical and scientific communities.

### By End User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US genotyping market, the distribution of market share among key end users highlights hospitals as the dominant player, leveraging their extensive networks and resources to implement advanced genotyping technologies. Diagnostic centers follow closely behind, experiencing a rapid ascent due to their focused services in genetic testing, which is expanding in demand as patients increasingly seek personalized medicine solutions.

The growth trends within this segment point towards a significant increase in the adoption of genotyping technologies, particularly driven by advancements in genomic research and the rising incidence of genetic disorders. Hospitals are capitalizing on their integrated healthcare systems to streamline genotyping processes, while diagnostic centers are emerging as critical players, offering specialized services that cater to an evolving healthcare landscape emphasizing precision and efficiency.

Hospitals (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals exhibit a dominant position in the US genotyping market, benefiting from their established infrastructures and broad access to patient populations. Their ability to integrate genotyping tests into routine clinical practices enhances their service offerings, making them indispensable in patient care. On the other hand, diagnostic centers are becoming significant contributors to the market by providing specialized and rapid testing services tailored to genetic conditions. They address niche demands with flexibility and efficiency, attracting a growing number of consumers seeking timely genetic assessments. As both segments evolve, collaboration between hospitals and diagnostic centers is expected to enhance service delivery and innovation in the realm of genetic testing.

## Competitive Benchmarking

The genotyping market exhibits a dynamic competitive landscape characterized by rapid technological advancements and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Agilent Technologies (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its product offerings and enhancing sequencing technologies, while Thermo Fisher Scientific (US) emphasizes its comprehensive portfolio and integration of digital solutions to streamline workflows. Agilent Technologies (US) is also investing in R&D to develop cutting-edge genotyping solutions, thereby contributing to a competitive environment that prioritizes technological superiority and customer-centric approaches.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce lead times and enhance responsiveness to market demands. This strategy not only improves operational efficiency but also allows for better alignment with regional regulatory requirements. The collective influence of these key players shapes a competitive landscape where innovation and operational excellence are paramount.
In October Illumina (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation sequencing technologies aimed at enhancing genomic research capabilities. This collaboration is expected to accelerate the development of innovative solutions that could significantly improve the accuracy and efficiency of genotyping processes. Such partnerships are indicative of a broader trend towards collaborative innovation in the market.
In September Thermo Fisher Scientific (US) launched a new line of genotyping assays designed to facilitate high-throughput screening in clinical settings. This product introduction not only strengthens its market position but also reflects the company's commitment to addressing the growing demand for rapid and reliable genotyping solutions. The launch is likely to enhance customer engagement and expand its footprint in the clinical diagnostics sector.
In August Agilent Technologies (US) expanded its global reach by establishing a new manufacturing facility in Asia, aimed at increasing production capacity for its genotyping products. This strategic move is anticipated to enhance supply chain efficiency and reduce costs, thereby positioning Agilent favorably against competitors. The establishment of this facility underscores the importance of geographical diversification in meeting global market demands.
As of November the competitive trends in the genotyping market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into workflows. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative efforts in driving innovation. The competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, reliability in supply chains, and the ability to deliver innovative solutions that meet the specific needs of diverse customer segments.

## Recent News & Developments

In recent months, the US Genotyping Market has witnessed significant developments, particularly with companies like Illumina, Thermo Fisher Scientific, and Qiagen. Notably, Illumina has launched new products enhancing genome sequencing accuracy, further solidifying its market position. In March 2023, Thermo Fisher Scientific announced its acquisition of a smaller biotech firm to expand its genotyping capabilities, augmenting its product offerings in the precision medicine space. This move is part of a broader trend where companies like Fulgent Genetics and Helix are increasing their Research and Development investments, which have been reported to enhance product pipelines and overall market competition. 

Growth in the market valuation of these companies reflects the rising demand for genotyping in areas such as personalized medicine and clinical diagnostics. Furthermore, the National Institutes of Health reported that federal funding for genomic research has substantially increased over the past two years, facilitating advancements in genotyping technology. Also, key partnerships between companies like Agilent Technologies and New England Biolabs have emerged to foster innovation in high-throughput genotyping solutions, indicating a collaborative approach to market challenges. All these developments highlight a vibrant and rapidly evolving landscape in the US Genotyping Market.

## Report Scope

| MARKET SIZE 2024 | 677.59(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 737.83(USD Million) |
| MARKET SIZE 2035 | 1728.56(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Qiagen (DE), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN) |
| Segments Covered | Technology, Product, Application, End User |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative genotyping technologies and services. |
| Key Market Dynamics | Technological advancements drive innovation in genotyping, enhancing precision and efficiency in genetic analysis. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US genotyping market in 2024?**
A: The overall market valuation was $677.59 Million in 2024.

**Q: What is the projected market valuation for the US genotyping market by 2035?**
A: The projected valuation for 2035 is $1728.56 Million.

**Q: What is the expected CAGR for the US genotyping market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 8.89%.

**Q: Which companies are considered key players in the US genotyping market?**
A: Key players include Illumina, Thermo Fisher Scientific, Qiagen, Roche, Agilent Technologies, Bio-Rad Laboratories, PerkinElmer, and BGI Genomics.

**Q: What are the main technology segments in the US genotyping market?**
A: Main technology segments include Sequencing, Capillary Electrophoresis, Polymerase Chain Reaction (PCR), and Others.

**Q: What was the market size for Sequencing technology in 2024?**
A: The market size for Sequencing technology was between $200.0 Million and $500.0 Million in 2024.

**Q: How much revenue did Reagents and Kits generate in the US genotyping market in 2024?**
A: Reagents and Kits generated revenue between $250.0 Million and $650.0 Million in 2024.

**Q: What applications are driving growth in the US genotyping market?**
A: Applications driving growth include Drug Discovery and Development, Academic Research, and Research and Development Centers.

**Q: Which end users are most prominent in the US genotyping market?**
A: Prominent end users include Hospitals, Diagnostic Centers, Academic Institutes, and Research and Development Centers.

**Q: What is the expected growth trend for the US genotyping market in the coming years?**
A: The market is expected to grow steadily, reaching $1728.56 Million by 2035, driven by advancements in technology and increasing applications.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-genotyping-market-18652*